Copyright
©The Author(s) 2016.
World J Gastroenterol. May 14, 2016; 22(18): 4484-4500
Published online May 14, 2016. doi: 10.3748/wjg.v22.i18.4484
Published online May 14, 2016. doi: 10.3748/wjg.v22.i18.4484
Table 1 Biochemical parameters of the different treatment groups
Group | ALT (U/L) | AST (U/L) | Bilirubin (mg/dL) | Albumin (g/L) | BUN (mmol/L) | Scr (μmol/L) |
Control (n = 8) | 43.3 ± 7.7 | 124 ± 14 | 0.3 ± 0.1 | 34.1 ± 3.4 | 8.7 ± 1.2 | 22.4 ± 4.0 |
OVX + CCl4 (n = 6) | 166 ± 10.1ab | 439 ± 19ab | 3.4 ± 0.3ab | 21.5 ± 2.8ab | 16.7 ± 1.8ab | 35.0 ± 4.7ab |
OVX + CCl4 + DPN (n = 7) | 86.1 ± 8.7a | 211 ± 15a | 1.7 ± 0.2a | 31.0 ± 3.3 | 9.6 ± 1.5 | 24.9 ± 4.5 |
OVX + CCl4 + DPN + PHTPP (n = 6) | 168 ± 10.2ab | 436 ± 23ab | 3.3 ± 0.4ab | 20.8 ± 2.0ab | 16.5 ± 2.1ab | 37.5 ± 4.6ab |
Table 2 In vivo hemodynamic data of the four treatment groups
Parameter | Control | OVX + CCl4 | OVX + CCl4 + DPN | OVX + CCl4 + DPN + PHTPP |
PP (mmHg) | 7.5 ± 1.1 | 14.9 ± 1.6a,c | 11.0 ± 1.3a | 14.6 ± 1.5a,c |
CO (mL/min per 100 g) | 19.3 ± 2.4 | 32.2 ± 5.0a,c | 25.7 ± 4.0a | 31.4 ± 5.4a,c |
MAP (mmHg) | 120.6 ± 14.2 | 82.1 ± 12.2a | 95.7 ± 14.0a | 89.5 ± 13.3a |
TPR (mmHg/mL/min per 100 g) | 6.0 ± 0.9 | 2.6 ± 0.3a | 3.1 ± 0.7a | 2.9 ± 0.6a |
PVI (mL/min per 100 g) | 2.1 ± 0.3 | 4.8 ± 0.8a,c | 3.0 ± 0.4a | 4.4 ± 0.6a,c |
SVR (mmHg/mL/min per 100 g) | 55.5 ± 8.5 | 15.0 ± 2.3a,c | 31.7 ± 3.7a | 16.8 ± 1.5a,c |
PSS (%) | 0.2 ± 0.1 | 50.5 ± 6.3a,c | 27.9 ± 4.9a | 48.1 ± 6.1a,c |
IHVR (mmHg/mL/min per 100 g) | 1.5 ± 0.2 | 3.2 ± 0.6a,c | 2.2 ± 0.3a | 3.0 ± 0.5a,c |
- Citation: Zhang CG, Zhang B, Deng WS, Duan M, Chen W, Wu ZY. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis. World J Gastroenterol 2016; 22(18): 4484-4500
- URL: https://www.wjgnet.com/1007-9327/full/v22/i18/4484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i18.4484